Altimmune reported positive topline Phase 2 results for its dual glucagon/GLP-1 agonist in alcohol use disorder, a potential step forward in a high-unmet-need m

Altimmune reported positive topline Phase 2 results for its dual glucagon/GLP-1 agonist in alcohol use disorder, a potential step forward in a high-unmet-need market. The RECLAIM study adds to its broader focus on liver and metabolic disease.